|

Bright Light Exposure in Surgical Patients

RECRUITINGN/ASponsored by University of Colorado, Denver
Actively Recruiting
PhaseN/A
SponsorUniversity of Colorado, Denver
Started2019-07-12
Est. completion2026-07
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
Locations1 site

Summary

1. Elucidate the influence of intense light therapy pretreatment in patients undergoing cardiac surgery. We hypothesize that intense light exposure is associated with the peripheral stabilization of Per2 in human buccal swabs and plasma samples before surgery and with a decrease of Troponin I levels after surgery. In addition, we hypothesize that light therapy leads to Per2 dependent metabolic optimization in the human cardiac tissue. Therefore, a small piece of human heart tissue from the right atrium will be collected during cardiac cannulation, which will be otherwise discarded. 2. Critical illness (being in the intensive care unit) results in circadian malfunction and vessels not working. Vessel function is controlled by the body's circadian clock. Intense light boosts the circadian clock and the vessel function in animal studies. Vessels not working well in critical ill patients results in a myriad of severe diseases (delirium, stroke, heart attack, organ damage etc). Thus we will test if intense light can be used to boost the circadian clock and the associated vessel function in critical ill patients.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients undergoing primary sternotomy cardiac surgery
* Subjects in the range of 18 - 90 years old .
* Patient need to be in sinus rhythm at the time of surgery.

Exclusion Criteria:

* patients \<18 or \>90 years old
* participation in other clinical trials within the previous 30 days
* pregnancy
* neurological conditions that could impair weaning from ventilator support
* significant CNS disorders or comorbid irreversible conditions with a six-month mortality rate more than 50 percent
* prisoners, or subjects with altered capabilities to make decision will be enrolled
* medical history of type 2 diabetes
* patients with atrial fibrillation or use of class III anti-arhythmic drug
* patients with a left ventricle ejection fraction \< 40%
* patient in emergency condition

Conditions4

Critical IllnessEndothelial DysfunctionHeart DiseaseMyocardial Ischemia

Locations1 site

University of Colorado Denver | Anschutz Medical Campus
Denver, Colorado, 80220-3706
Nick M Naughton, BS303-724-0833NICK.NAUGHTON@CUANSCHUTZ.EDU

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.